🤖 WhiteLab Genomics: AI for DNA and RNA therapies
Accelerated discovery and development with AI/ML
This week’s AI company WhiteLab Genomics uses AI to develop novel DNA and RNA therapies.
⚾ The Elevator Pitch
RNA therapy is the treatment or prevention of diseases using RNA-based molecules. Research on clinical use of RNA therapy began in the 1990s with significant success in cancer therapy in the 2010s. And recently, the advent of RNA-based vaccines has further highlighted its use. The process for developing RNA and DNA based therapies is extremely time-consuming and complex. This is where WhiteLab Genomix comes into play.
WhiteLab Genomix taps into AI/ML to help their customers develop more genomic medicines, faster, in leaner ways and make those revolutionary drugs more accessible to patients in need.
👇 The drop down
Traction: YC backed, raised $10m from Omnes Capital and Debiopharm
🔍 Why we like it
☀️ Faster and cheaper development of biotherapies
Current methodologies in developing new therapies typically involve scientists developing scientific hypotheses. If they work, great, they move on. If they fail, it’s back to square one. It’s an exhaustive process that can take consume a lot of time and money. This is where WhiteLab Genomics comes into play. Using AI and machine learning, they develop multiple feasible scientific hypotheses all at once, looking at different genetic variants to predict the best molecular design for therapy. More and better hypotheses means faster and cheaper developments of biotherapies in the long run.
🧠 Knowledge = Power
WhiteLab Genomics trains their models on large amounts of curated and validated datasets, which include public databases but also proprietary data from partners. These expansive models are then interconnected within their Knowledge Graph Database which ultimately predicts biological features from new genetic sequences to build new therapeutic vectors. This knowledge “moat” gives them a leg up in producing cutting edge biotherapies. The company is currently working on DNA-based treatments for conditions such as lyosomal diseases and sickle cell disease.